Variable name;level;Overall;Curie Paris;Curie St Cloud;p;test
;n;1357;818;538;;
Age;[0 -40);801 (59.1);485 (59.4);316 (58.7);NaN;
;40+;554 (40.9);332 (40.6);222 (41.3);;
Age (mean);;38.7 [34.9, 41.6];38.6 [34.6, 41.6];38.9 [35.4, 41.6];0.108;nonnorm
Number of children;0;373 (27.5);254 (31.1);118 (21.9);NaN;
;1;279 (20.6);171 (20.9);108 (20.1);;
;More than 1;705 (52.0);393 (48.0);312 (58.0);;
BMI;<18.5;79 (6.3);51 (6.2);28 (6.5);NaN;
;25-29.9;257 (20.6);165 (20.2);91 (21.1);;
;>=30;107 (8.6);60 (7.3);47 (10.9);;
;18.5-24.9;807 (64.6);541 (66.2);266 (61.6);;
BMI (mean);;22.6 [20.5, 25.5];22.4 [20.4, 25.3];23.0 [20.7, 26.5];0.013;nonnorm
Genetic Analysis;No;656 (48.3);358 (43.8);298 (55.4);NaN;
;Yes;701 (51.7);460 (56.2);240 (44.6);;
Hereditary predisposition;No;547 (79.6);347 (77.1);199 (84.3);NaN;
;Yes;140 (20.4);103 (22.9);37 (15.7);;
Inflammatory BC;No;1338 (98.7);808 (98.8);530 (98.5);NaN;
;Yes;18 (1.3);10 (1.2);8 (1.5);;
Clinical Tumor size (mm);;30.3 (21.7);30.6 (21.9);29.8 (21.4);0.503;
Clinical N stage (TNM);N0;854 (63.4);479 (58.8);375 (70.6);NaN;
;N1-N2-N3;492 (36.6);336 (41.2);156 (29.4);;
SBR grade;Grade I-II;586 (43.5);329 (40.5);257 (48.1);NaN;
;Grade III;760 (56.5);483 (59.5);277 (51.9);;
Histological type;NST;1265 (93.4);764 (93.4);501 (93.3);NaN;
;Lobular;54 (4.0);37 (4.5);17 (3.2);;
;Others;36 (2.7);17 (2.1);19 (3.5);;
Neoajuvant chemotherapy;No;744 (54.9);421 (51.5);323 (60.0);NaN;
;Yes;612 (45.1);397 (48.5);215 (40.0);;
Chemotherapy setting;NAC;611 (45.1);397 (48.5);214 (39.8);NaN;
;Adjuvant;744 (54.9);421 (51.5);323 (60.0);;
;NAC and adjuvant;0 (0.0);0 (0.0);0 (0.0);;
;Chemotherapy without surgery;1 (0.1);0 (0.0);1 (0.2);;
;No;0 (0.0);0 (0.0);0 (0.0);;
Fertility preservation discussion;No;909 (67.0);531 (64.9);378 (70.3);NaN;
;Yes;447 (33.0);287 (35.1);160 (29.7);;
